Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EMA Recommends GSK’s Groundbreaking Gene Therapy

By Drug Discovery Trends Editor | April 4, 2016

The European Medicines Agency (EMA) recommended approval for a gene therapy named Strimvelis, which is made by GlaxoSmithKline.

Strimvelis is for treating a rare condition called ADA Severe Combined Immune Deficiency (ADA-SCID), reports Reuters. The disease prevents individuals from forming a certain type of white blood cell, which impacts their immune system.

An estimated 15 children are born with this year condition per year in Europe, and survival rates are low. Patients diagnosed with this disorder usually don’t survive more than two years unless a suitable bone marrow transplant is made.

However, Reuters notes the rarity of this disease has made it difficult to find a matching bone marrow transplant.

The drug operates in two phases, writes FierceBiotech. First, it uses a viral vector to target stem cells extracted from bone marrow and to insert healthy versions of the ADA gene into those cells. Next, the patient’s immune system begins repairing itself after the cells are reintroduced into the body.

Researchers saw exceptionally high survival rates in patients participating in the clinical trial with no adverse events reported.

A final decision from the EU is expected within the next few months. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50